This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Academy Of Managed Care Pharmacy Announces New Editor-in-Chief For Journal Of Managed Care Pharmacy

ALEXANDRIA, Va., Feb. 6, 2013 /PRNewswire-USNewswire/ -- The Academy of Managed Care Pharmacy (AMCP) is pleased to announce the appointment of John Mackowiak, PhD, as Editor-in-Chief of the Journal of Managed Care Pharmacy (JMCP). Mackowiak takes up his duties immediately.

(Logo: http://photos.prnewswire.com/prnh/20110804/DC47695LOGO)

Mackowiak was selected following a rigorous nationwide search by the JMCP Editor-in-Chief Search Committee, a group comprised of AMCP leaders and JMCP Editorial Advisory Board members.

"We reviewed several excellent candidates for this position," said Eric Cannon, a member of the AMCP Board of Directors and the Chair of the JMCP Search Committee. "John's vast qualifications, including his many years of research experience and vision for JMCP moving forward, provided the winning edge."

Mackowiak most recently has been an independent outcomes researcher focusing on research design, assessment instrument development, data analysis, economic modeling and scientific writing. He also has served as the Director of Outcomes Research for pharmaceutical manufacturer Glaxo and Glaxo Wellcome, and was an Associate Professor and Acting Division Chair at the College of Pharmacy at the University of North Carolina-Chapel Hill.

Mackowiak earned a Ph.D. in Pharmacy Administration from the University of North Carolina at Chapel Hill. He also holds a Bachelor of Science degree with honors and a Master of Science in Pharmacy Administration from the University of Illinois at Chicago.

"We are delighted to have John take over the reins of JMCP, one of the most highly respected medical journals in the country today," said AMCP Chief Executive Officer Edith A. Rosato, RPh, IOM. "We look forward to his tenure at AMCP and the continuation of JMCP as a platform for publishing important research on the value of pharmaceutical products and managed pharmacy benefits, which cover more than 200 million Americans."

JMCP publishes peer-reviewed original research manuscripts, subject reviews, and other content intended to advance the use of the scientific method, including the interpretation of research findings in managed care pharmacy. The journal is dedicated to improving the quality of care delivered to patients served by managed care pharmacy by providing its readers with the results of scientific investigation and evaluation of clinical, health, service, and economic outcomes of pharmacy services and pharmaceutical interventions, including formulary management.

The JMCP Editor-in-Chief determines the editorial content with suggestions from the Editorial Advisory Board. The views and opinions expressed in JMCP do not necessarily reflect or represent official policy of AMCP or the authors' institutions unless specifically stated.

For more information on AMCP, visit www.amcp.org. For more information on the Journal of Managed Care Pharmacy, visit www.amcp.org/JMCPhome.aspx.

About AMCP

The Academy of Managed Care Pharmacy (AMCP) is a national professional association of pharmacists and other health care practitioners who serve society by the application of sound medication management principles and strategies to improve health care for all. The Academy's nearly 7,000 members develop and provide a diversified range of clinical, educational and business management services and strategies on behalf of the more than 200 million Americans covered by a managed care pharmacy benefit. AMCP will celebrate its 25th anniversary in 2013. More news and information about AMCP can be obtained on its website, at www.amcp.org

SOURCE Academy of Managed Care Pharmacy

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,976.31 +263.65 1.49%
S&P 500 2,086.88 +25.86 1.25%
NASDAQ 4,947.0330 +55.8140 1.14%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs